Biogen Idec, Swedish Orphan Biovitrum publicize advancement of rFVIIIFc into registrational ruminate on
Biogen Idec (NASDAQ: BIIB) and Swedish Orphan Biovitrum (STO: SOBI) today announced that they lay out to contribute to the companies’ long-lasting, fully-recombinant proxy VIII Fc fusion protein (rFVIIIFc) into a registrational clinical test in people with hemophilia A. The conclusiveness to put the program is based on auspicious matter from a Aspect 1/2a open-label, cross-over, multi-center, dose-escalation cramming that evaluated the cover and pharmacokinetics of an intravenous injection of rFVIIIFc in 16 previously-treated patients with strict hemophilia A. In the haunt, rFVIIIFc was expressively tolerated and demonstrated a prolonged half-life compared to Advate® (antihemophilic lender recombinant, plasma/albumin-free method, rFVIII), supporting advancement of the program.
“Biogen Idec is committed to transforming the lives of people with hemophilia through developing a portfolio of long-lasting therapies”
No related posts.
Related posts brought to you by Yet Another Related Posts Plugin.
